Drug and alcohol use among patients with schizophrenia and related psychoses: Levels and consequences

Schizophrenia Research

Volumn 67, Issue 2-3, 2004, Pages 157-166

  Margolese, Howard C ^a,b   Malchy, Leslie ^a   Negrete, Juan Carlos ^a,b   Tempier, Raymond ^a,b   Gill, Kathryn ^a,b,c  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

Alcohol; Cannabis; Comorbidity; Dual diagnosis; Nicotine; Schizoaffective disorder; Schizophrenia; Substance abuse

Indexed keywords

ALCOHOL; AMPHETAMINE; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; CAFFEINE; CENTRAL NERVOUS SYSTEM AGENTS; COCAINE; DIAMORPHINE; NARCOTIC AGENT; NEUROLEPTIC AGENT; NICOTINE; PSYCHEDELIC AGENT; TRANQUILIZER;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CANADA; CANNABIS ADDICTION; CIGARETTE SMOKING; COCAINE DEPENDENCE; COHORT ANALYSIS; COMMUNITY MENTAL HEALTH CENTER; DEPRESSION; DRUG BLOOD LEVEL; DRUG DEPENDENCE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; NEGATIVE SYNDROME; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; PSYCHOSIS; RATING SCALE; SCHIZOPHRENIA; TOBACCO DEPENDENCE;

EID: 1342343073     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(02)00523-6     Document Type: Article

References (57)

1. Abelson, H., Fishburne, R.M., Cisin, I., 2002. National survey on drug abuse: 1977.
2. Adler L.E., Olincy A., Waldo M., Harris J.G., Griffith J., Stevens K., Flach K., Nagamoto H., Bickford P., Leonard S., Freedman R. Schizophrenia, sensory gating and nicotinic receptors. Schizophr. Bull. 24:1998;189-202.
3. Alterman A.I., Erdlen F.R., Murphy E. Alcohol abuse in the psychiatric hospital population. Addict. Behav. 6:1981;69-73.
4. Angermeyer M.C. Schizophrenia and violence. Acta Psychiatr. Scand., Suppl. 102:2000;63-67.
5. Barbee J.G., Clark P.D., Crapanzano M.S., Heintz G.C., Kehoe C.E. Alcohol and substance abuse among schizophrenic patients presenting to an emergency psychiatric service. J. Nerv. Ment. Dis. 177:1989;400-407.
6. Brady K., Anton R., Ballenger J.C., Lydiard R.B., Adinoff B., Selander J. Cocaine abuse among schizophrenic patients. Am. J. Psychiatry. 147:1990;1164-1167.
7. Brady K., Casto S., Lydiard R.B., Malcolm R., Arana G. Substance abuse in an inpatient psychiatric sample. Am. J. Drug Alcohol Abuse. 17:1991;389-397.
8. Breen R., Thornhill J.T. Noncompliance with medication for psychiatric disorders. CNS Drugs. 9:1998;457-471.
9. Callaghan J.T., Bergstrom R.F., Ptak L.R., Beasley C.M. Olanzapine: pharmacokinetic and pharmacodynamic profile. Clin. Pharmacokinet. 37:1999;177-193.
10. Cantwell R., Brewin J., Glazebrook C., Dalkin T., Fox R., Medley I., Harrison G. Prevalence of substance misuse in first-episode psychosis. Br. J. Psychiatry. 174:1999;150-153.
11. Carise D., McLellan A.T., Cacciola J., Love M., Cook T., Bovasso G., Lam V. Suggested specifications for a standardized Addiction Severity Index database. J. Subst. Abuse Treat. 20:2001;239-244.
12. Caspari D. Cannabis and schizophrenia: results of a follow-up study. Eur. Arch. Psychiatry Clin. Neurosci. 249:1999;45-49.
13. Cohen M., Klein D.F. Drug abuse in a young psychiatric population. Am. J. Orthopsychiatr. 40:1970;448-455.
14. Derogatis L.R., Melisaratos N. The Brief Symptom Inventory: an introductory report. Psychol. Med. 13:1983;595-605.
15. Dervaux A., Bayle F.J., Laqueille X., Bourdel M.C., Le Borgne M.H., Olie J.P., Krebs M.O. Is substance abuse in schizophrenia related to impulsivity, sensation seeking, or anhedonia? Am. J. Psychiatry. 158:2001;492-494.
16. Difranza J.R., Guerrera P. Alcoholism and smoking. J. Stud. Alcohol Abuse. 51:1990;130-135.
17. Dixon L., Haas G., Weiden P.J., Sweeney J., Frances A.J. Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am. J. Psychiatry. 148:1991;224-230.
18. Drake R.E., Osher F.C., Wallach M.A. Alcohol use and abuse in schizophrenia. A prospective community study. J. Nerv. Ment. Dis. 177:1989;408-414.
19. Drake R.E., Osher F.C., Noordsy D.L., Hurlbut S.C., Teague G.B., Beaudett M.S. Diagnosis of alcohol use disorders in schizophrenia. Schizophr. Bull. 16:1990;57-67.
20. Drake R.E., Bartels S.J., Teague G.B., Noordsy D.L., Clark R.E. Treatment of substance abuse in severely mentally ill patients. J. Nerv. Ment. Dis. 181:1993;606-611.
21. Duke P.J., Pantelis C., McPhillips M.A., Barnes T.R.E. Comorbid non-alcohol substance misuse among people with schizophrenia. Br. J. Psychiatry. 179:2001;509-513.
22. el Guebaly N., Hodgins D.C. Schizophrenia and substance abuse: prevalence issues. Can. J. Psychiatry. 37:1992;704-710.
23. Fenton W.S., Blyler C.R., Heinssen R.K. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr. Bull. 23:1997;637-651.
24. Fowler I.L., Carr V.J., Carter N.T., Lewin T.J. Patterns of current and lifetime substance use in schizophrenia. Schizophr. Bull. 24:1998;443-455.
25. Gogek E.B. Prevalence of substance abuse in psychiatric patients. Am. J. Psychiatry. 148:1991;1086.
26. Hambrecht M., Hafner H. Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective. Aust. N. Z. J. Psychiatry. 34:2000;468-475.
27. Hambrecht M., Hafner H. Substance abuse and the onset of schizophrenia. Biol. Psychiatry. 40:1996;1155-1163. (December 1).
28. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry. 23:1960;56-62.
29. Havassy B.E., Arns P.G. Relationship of cocaine and other substance dependence to well-being of high-risk psychiatric patients. Psychiatr. Serv. 49:1998;935-940.
30. Heyscue B.E., Levin G.M., Merrick J.P. Compliance with depot antipsychotic medication by patients attending outpatient clinics. Psychiatr. Serv. 49:1998;1232-1234.
31. Hughes J.R. Clinical implications of the association between smoking and alcoholism. Fertig J.B., Allen J.P. Alcohol and Tobacco: from Basic Science to Clinical Practice. NIAAA Research Monograph No. 30. 1995;National Institutes of Health, Bethesda, MD.
32. Hymowitz N., Jaffe F.E., Gupta A., Feuerman M. Cigarette smoking among patients with mental retardation and mental illness. Psychiatr. Serv. 48:1997;100-102.
33. Kamali, M., Kelly, L., Gervin, M., Browne, S., Larkin, C., O'Callaghan, E., 2001. Psychopharmacology: insight and comorbid substance misuse and medication compliance among patients with schizophrenia. Psychiatr. Serv. 52, 161-163, 166.
34. Kay S.R., Opler L.A., Lindenmayer J.P. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res. 23:1988;99-110.
35. Kay S.R., Opler L.A., Lindenmayer J.P. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br. J. Psychiatr., Suppl. 1989;59-67.
36. Kendler K.S., Gallagher T.J., Abelson J.M., Kessler R.C. Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample. Arch. Gen. Psychiatry. 53:1996;1022-1031.
37. Lane R.D., Glazer W.M., Hansen T.E., Berman W.H., Kramer S.I. Assessment of tardive dyskinesia using the Abnormal Involuntary Movement Scale. J. Nerv. Ment. Dis. 173:1985;353-357.
38. McLellan A.T., Luborsky L., Woody G.E., O'Brien C.P. An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. J. Nerv. Ment. Dis. 168:1980;26-33.
39. McLellan A.T., Luborsky L., Cacciola J., Griffith J., Evans F., Barr H.L., O'Brien C.P. New data from the Addiction Severity Index. Reliability and validity in three centers. J. Nerv. Ment. Dis. 173:1985;412-423.
40. Meyer J.M. Individual changes in clozapine levels after smoking cessation: results and a predictive model. J. Clin. Psychopharmacol. 21:2001;569-574.
41. Negrete J.C., Knapp W.P., Douglas D.E., Smith W.B. Cannabis affects the severity of schizophrenic symptoms: results of a clinical survey. Psychol. Med. 16:1986;515-520.
42. Nemeroff C.G., DeVane C.L., Pollack B.G. Newer antidepressants and the cytochrome P450 system. Am. J. Psychiatry. 153:1996;311-320.
43. Olfson M., Mechanic D., Hansell S., Boyer C.A., Walkup J., Weiden P.J. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr. Serv. 51:2000;216-222.
44. Pulver A.E., Wolyniec P.S., Wagner M.G., Moorman C.C., McGrath J.A. An epidemiologic investigation of alcohol-dependent schizophrenics. Acta Psychiatr. Scand. 79:1989;603-612.
45. Regier D.A., Farmer M.E., Rae D.S., Locke B.Z., Keith S.J., Judd L.L., Goodwin F.K. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA. 264:1990;2511-2518. (November 21).
46. Schneier F.R., Siris S.G. A review of psychoactive substance use and abuse in schizophrenia. Patterns of drug choice. J. Nerv. Ment. Dis. 175:1987;641-652.
47. Seibyl J.P., Satel S.L., Anthony D., Southwick S.M., Krystal J.H., Charney D.S. Effects of cocaine on hospital course in schizophrenia. J. Nerv. Ment. Dis. 181:1993;31-37.
48. Sevy S., Kay S.R., Opler L.A., van Praag H.M. Significance of cocaine history in schizophrenia. J. Nerv. Ment. Dis. 178:1990;642-648.
49. Simpson G.M., Lee J.H., Zoubok B., Gardos G. A rating scale for tardive dyskinesia. Psychopharmacology (Berl.). 64:1979;171-179. (August 8).
50. Soyka M. Substance misuse, psychiatric disorder and violent and disturbed behaviour. Br. J. Psychiatry. 176:2000;345-350.
51. Soyka M., Albus M., Kathmann N., Finelli A., Hofstetter S., Holzbach R., Immler B., Sand P. Prevalence of alcohol and drug abuse in schizophrenic inpatients. Eur. Arch. Psychiatry Clin. Neurosci. 242:1993;362-372.
52. Swartz M.S., Swanson J.W., Hiday V.A., Borum R., Wagner H.R., Burns B.J. Violence and severe mental illness: the effects of substance abuse and non adherence to medication. Am. J. Psychiatry. 155:1998;226-231.
53. True W., Xian H., Scherrer J.F., Madden P.A., Bucholz K.K., Heath A.C., Eisen S.A., Lyons M.J., Goldberg J., Tsuang M. Common genetic vulnerability for nicotine and alcohol dependence in men. Arch. Gen. Psychiatry. 56:1999;655-661.
54. van der W.J., Steijns L.S. Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology. Ann. Clin. Biochem. 36(Pt 6):1999;722-729.
55. Van Dongen C.J. Smoking and persistent mental illness: an exploratory study. J. Psychosoc. Nurs. Ment. Health Serv. 37:1999;26-34.
56. Zeidonis D.M., George T.P. Schizophrenia and smoking: report of a pilot smoking cessation program and review of neurobiological and clinical issues. Schizophr. Bull. 23:1997;247-254.
57. Ziedonis D., Richardson T., Lee E., Petrakis I., Kosten T. Adjunctive desipramine in the treatment of cocaine abusing schizophrenics. Psychopharmacol. Bull. 28:1992;309-314.